OEI yields 3.81% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, OEI + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OEI + PFE for your $10,000?
OEI targets roughly 90% allocation to large-cap US equities while utilizing an options overlay strategy. Stock selection combines top-down market analysis, evaluating value, quality, and volatility, with bottom-up research on company fundamentals and earnings potential. To enhance income beyond dividends, the fund writes OTM call options on individual stocks, equity indexes, or ETFs. These options are written on 25-75% of the funds equity holdings, with each contract generally covering a specified portion of the underlying assets, and typically expire within one to six months. Additionally, the fund may also purchase OTM put and call options. The calls help retain upside participation, while puts provide downside protection. The strategy seeks to provide a consistent income stream and reduced volatility compared to traditional equity ETFs, though upside potential is capped in strong bull markets due to call-writing. The fund may have a high portfolio turnover rate.
Full OEI Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.